Evacetrapib is one of two CETP inhibitors currently being evaluated (the other being anacetrapib). Two other CETP inhibitors (torcetrapib and dalcetrapib) were discontinued during trials due to increased deaths and little identifiable cardiovascular benefit (despite substantial increases in HDL). Some hypothesize that CETP inhibitors may still be useful in the treatment of dyslipidemia, though significant caution is warranted.
In a 2014 study in 165 Japanese patients Evacetrapib decreased CETP activity alone or in combination with atorvastatin. Phase III trials are running with completion expected in 2016. ACCELERATE is studying evacetrapib in participants with high-risk vascular disease. ACCENTUATE is studying patients with hyperlipidemia or diabetes.
^Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE (2011). "Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol". JAMA306 (19): 2099–109. doi:10.1001/jama.2011.1649.
^"Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.". Am J Cardiol. Jun 15, 2014. PMID24786356.